MX360258B - Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos. - Google Patents

Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos.

Info

Publication number
MX360258B
MX360258B MX2015008779A MX2015008779A MX360258B MX 360258 B MX360258 B MX 360258B MX 2015008779 A MX2015008779 A MX 2015008779A MX 2015008779 A MX2015008779 A MX 2015008779A MX 360258 B MX360258 B MX 360258B
Authority
MX
Mexico
Prior art keywords
constant domains
compositions
antibody fragments
new antibody
polypeptide
Prior art date
Application number
MX2015008779A
Other languages
English (en)
Other versions
MX2015008779A (es
Inventor
Vigna Elisa
Michieli Paolo
Maria Comoglio Paolo
Original Assignee
Metheresis Translational Res S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res S A filed Critical Metheresis Translational Res S A
Publication of MX2015008779A publication Critical patent/MX2015008779A/es
Publication of MX360258B publication Critical patent/MX360258B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un fragmento de anticuerpo que comprende un primer polipéptido que comprende un dominio variable de cadena ligera y dos dominios constantes y un segundo polipéptido que comprende un dominio variable de cadena pesada y dos dominios constantes, en donde dos dominios constantes son dominios constantes de cadena ligera y dos dominios constantes son dominios constantes de cadena pesada CH1.
MX2015008779A 2013-01-09 2014-01-07 Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos. MX360258B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000012A ITTO20130012A1 (it) 2013-01-09 2013-01-09 Nuovi frammenti anticorpali, relative composizioni ed usi
PCT/IB2014/058098 WO2014108829A1 (en) 2013-01-09 2014-01-07 New antibody fragments, compositions and uses thereof

Publications (2)

Publication Number Publication Date
MX2015008779A MX2015008779A (es) 2016-03-31
MX360258B true MX360258B (es) 2018-10-26

Family

ID=47790367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008779A MX360258B (es) 2013-01-09 2014-01-07 Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos.

Country Status (28)

Country Link
US (2) US9975952B2 (es)
EP (1) EP2943510B1 (es)
JP (1) JP6382842B2 (es)
KR (1) KR102155392B1 (es)
CN (1) CN104968684B (es)
AU (1) AU2014206130A1 (es)
BR (1) BR112015016447A8 (es)
CA (1) CA2896929C (es)
CL (1) CL2015001939A1 (es)
DK (1) DK2943510T3 (es)
EA (1) EA031536B1 (es)
ES (1) ES2674491T3 (es)
HR (1) HRP20180917T1 (es)
HU (1) HUE037843T2 (es)
IL (1) IL239704B (es)
IT (1) ITTO20130012A1 (es)
LT (1) LT2943510T (es)
ME (1) ME03080B (es)
MX (1) MX360258B (es)
PH (1) PH12015501539A1 (es)
PL (1) PL2943510T3 (es)
PT (1) PT2943510T (es)
RS (1) RS57286B1 (es)
SG (1) SG11201505114VA (es)
SI (1) SI2943510T1 (es)
TR (1) TR201808826T4 (es)
WO (1) WO2014108829A1 (es)
ZA (1) ZA201504748B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
CN113480645B (zh) * 2021-07-16 2022-11-11 甘肃中科博瑞生物工程有限公司 一种抗幽门螺旋杆菌重组抗体、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
SG169382A1 (en) * 2006-02-06 2011-03-30 Metheresis Translational Res S A Ch Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
CN103183738B (zh) * 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2720136T3 (es) * 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
HUE039703T2 (hu) * 2011-08-23 2019-01-28 Roche Glycart Ag Bispecifikus antigénkötõ molekulák

Also Published As

Publication number Publication date
HRP20180917T1 (hr) 2018-08-10
RS57286B1 (sr) 2018-08-31
US20160017044A1 (en) 2016-01-21
ES2674491T3 (es) 2018-07-02
SG11201505114VA (en) 2015-07-30
HUE037843T2 (hu) 2018-09-28
US20180237527A1 (en) 2018-08-23
ITTO20130012A1 (it) 2014-07-10
PT2943510T (pt) 2018-07-02
JP2016503069A (ja) 2016-02-01
DK2943510T3 (en) 2018-07-02
KR20150103283A (ko) 2015-09-09
CN104968684B (zh) 2019-06-28
TR201808826T4 (tr) 2018-07-23
IL239704B (en) 2019-03-31
SI2943510T1 (en) 2018-08-31
ME03080B (me) 2019-01-20
EA201591279A1 (ru) 2015-11-30
LT2943510T (lt) 2018-07-10
WO2014108829A1 (en) 2014-07-17
CA2896929C (en) 2020-09-29
US9975952B2 (en) 2018-05-22
EA031536B1 (ru) 2019-01-31
KR102155392B1 (ko) 2020-09-11
BR112015016447A8 (pt) 2018-01-23
AU2014206130A1 (en) 2015-07-30
US10351628B2 (en) 2019-07-16
CN104968684A (zh) 2015-10-07
CL2015001939A1 (es) 2016-04-01
JP6382842B2 (ja) 2018-08-29
EP2943510B1 (en) 2018-05-23
EP2943510A1 (en) 2015-11-18
CA2896929A1 (en) 2014-07-17
MX2015008779A (es) 2016-03-31
PH12015501539A1 (en) 2015-10-05
PL2943510T3 (pl) 2018-09-28
ZA201504748B (en) 2019-11-27
IL239704A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
PH12017502180A1 (en) Tau-binding antibodies
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EP3702372A3 (en) Anti-cd40 human antibodies
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201690314A1 (ru) Анти-garp-белок и его применения
MX351418B (es) Fragmentos fab de anticuerpo mutado multiespecifico.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EP4324518A3 (en) Antibody molecules to tim-3 and uses thereof
SG10201909716RA (en) Modified j-chain
PH12017502207A1 (en) Tau-binding antibodies
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
EP3024850A4 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
PH12015501539A1 (en) New antibody fragments, compositions and uses thereof
EA201291065A1 (ru) Антитела против vla-4
EP3095796A4 (en) Anti-human probdnf monoclonal antibody, and uses thereof in pains
CY1124445T1 (el) Αντισωματα αντι-ccl17
EA201591709A1 (ru) 5-бром-индирубины
EA201500551A1 (ru) Серно-цементный продукт
UY4267Q (es) Botella
UY4262Q (es) Botella
UY4163Q (es) Botella

Legal Events

Date Code Title Description
FG Grant or registration